DNL310

About Denali Therapeutics

Denali Therapeutics is on a mission to defeat neurodegeneration by creating medicines that cross biological barriers, particularly the blood-brain barrier. Founded in 2015, the company has established its proprietary TransportVehicle™ (TV) platform as a core competitive moat, enabling the delivery of therapeutic antibodies, enzymes, and other biologics into the central nervous system. Its strategy leverages this platform to build a broad pipeline targeting diseases like Parkinson's, Alzheimer's, ALS, and lysosomal storage disorders, with key programs advancing through mid- to late-stage clinical trials. Denali has secured major partnerships with industry leaders like Biogen and Takeda, validating its approach and providing non-dilutive capital to fuel its ambitious R&D agenda.

Therapeutic Areas

Other Hunter syndrome (MPS II) Drugs